ReCerise Therapeutics Inc. ("ReCerise"), a company committed to research and development of first-in-class therapeutics in oncology, recently entered a research partnership with the National Cancer ...

ReCerise Therapeutics Inc. ("ReCerise"), a company committed to research and development of first-in-class therapeutics in oncology, recently entered a research partnership with the National Cancer ...

Oracle Health has been recognized as a leader in the IDC MarketScape: U.S. Healthcare Data Platform for Providers 2024-25 Vendor Assessment 1. The report notes: "With a strong emphasis on ...

Illumina announces a new NGS-based spatial technology kit and new software platform, Illumina Connected Multiomics.

Velsera, a leading global healthcare technology company offering a universal software platform to connect clinical care with discovery, today reflected on a number of key achievements to date that ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

The Protein Sequencing Companytm, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology ...

The interactions between plants and microorganisms — encompassing symbiosis, biocontrol, and pathogenic encounters — play a ...

Since the Arkansas Integrative Metabolic Research Center was established in 2021, supported researchers have secured over $34 million in external research funding and a majority of NIH funding on ...

Scientists in Cambridge have developed a new ‘super test’ for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.

Stephens Inc. AR reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 4.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 14,439 shares ...